Advertisement
Screener

Alkermes plc. (ALKS) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

Alkermes plc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Alkermes plc. (ALKS) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$65.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-07-28

  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $501.00K, a 99.42% decline year-over-year.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$66.48M, a 395.94% decline year-over-year.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $49.34M, a 66.32% decline year-over-year.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $82.76M, a 10.41% decline year-over-year.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $241.66M, a 34.16% decline from fiscal 2024.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $367.07M, a 3.18% increase from fiscal 2023.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $355.76M.
  • Alkermes plc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$158.27M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2026-06-30$501.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28
-$65.98M
10-Q · filed 2026-07-28
-$16.64M
derived: sum of 3 quarters · filed 2026-07-28
$66.12M
derived: sum of 4 quarters · filed 2026-07-28
2026-03-31-$66.48M
10-Q · filed 2026-05-05
-$17.14M
derived: sum of 2 quarters · filed 2026-05-05
$65.62M
derived: sum of 3 quarters · filed 2026-05-05
$152.72M
derived: sum of 4 quarters · filed 2026-07-28
2025-12-31$49.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$132.10M
derived: sum of 2 quarters · filed 2026-02-25
$219.20M
derived: sum of 3 quarters · filed 2026-07-28
$241.66M
10-K · filed 2026-02-25
2025-09-30$82.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$169.86M
derived: sum of 2 quarters · filed 2026-07-28
$192.32M
10-Q · filed 2025-10-28
$338.83M
derived: sum of 4 quarters · filed 2026-07-28
2025-06-30$87.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28
$109.56M
10-Q · filed 2026-07-28
$256.06M
derived: sum of 3 quarters · filed 2026-07-28
$348.45M
derived: sum of 4 quarters · filed 2026-07-28
2025-03-31$22.46M
10-Q · filed 2026-05-05
$168.97M
derived: sum of 2 quarters · filed 2026-05-05
$261.35M
derived: sum of 3 quarters · filed 2026-05-05
$352.71M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$146.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$238.88M
derived: sum of 2 quarters · filed 2026-02-25
$330.24M
derived: sum of 3 quarters · filed 2026-02-25
$367.07M
10-K · filed 2026-02-25
2024-09-30$92.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$183.74M
derived: sum of 2 quarters · filed 2025-10-28
$220.57M
10-Q · filed 2025-10-28
$333.35M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$91.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29
$128.19M
10-Q · filed 2025-07-29
$240.97M
derived: sum of 3 quarters · filed 2026-02-25
$288.72M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$36.83M
10-Q · filed 2025-05-01
$149.61M
derived: sum of 2 quarters · filed 2026-02-25
$197.37M
derived: sum of 3 quarters · filed 2026-02-25
$434.43M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$112.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$160.54M
derived: sum of 2 quarters · filed 2026-02-25
$397.60M
derived: sum of 3 quarters · filed 2026-02-25
$355.76M
10-K · filed 2026-02-25
2023-09-30$47.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24
$284.82M
derived: sum of 2 quarters · filed 2024-10-24
$242.98M
10-Q · filed 2024-10-24
$214.72M
derived: sum of 4 quarters · filed 2025-02-12
2023-06-30$237.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24
$195.22M
10-Q · filed 2024-07-24
$166.97M
derived: sum of 3 quarters · filed 2025-02-12
$102.99M
derived: sum of 4 quarters · filed 2025-02-12
2023-03-31-$41.84M
10-Q · filed 2024-05-01
-$70.10M
derived: sum of 2 quarters · filed 2025-02-12
-$134.07M
derived: sum of 3 quarters · filed 2025-02-12
-$164.21M
derived: sum of 4 quarters · filed 2025-02-12
2022-12-31-$28.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12
-$92.23M
derived: sum of 2 quarters · filed 2025-02-12
-$122.36M
derived: sum of 3 quarters · filed 2025-02-12
-$158.27M
10-K · filed 2025-02-12
2022-09-30-$63.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25
-$94.11M
derived: sum of 2 quarters · filed 2023-10-25
-$130.01M
10-Q · filed 2023-10-25
-$129.14M
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30-$30.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26
-$66.04M
10-Q · filed 2023-07-26
-$65.17M
derived: sum of 3 quarters · filed 2024-02-21
-$94.15M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31-$35.90M
10-Q · filed 2023-04-26
-$35.03M
derived: sum of 2 quarters · filed 2024-02-21
-$64.02M
derived: sum of 3 quarters · filed 2024-02-21
-$61.65M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$873.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
-$28.11M
derived: sum of 2 quarters · filed 2024-02-21
-$25.75M
derived: sum of 3 quarters · filed 2024-02-21
-$48.17M
10-K · filed 2024-02-21
2021-09-30-$28.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
-$26.62M
derived: sum of 2 quarters · filed 2022-11-02
-$49.04M
10-Q · filed 2022-11-02
-$91.68M
derived: sum of 4 quarters · filed 2023-02-16
2021-06-30$2.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27
-$20.05M
10-Q · filed 2022-07-27
-$62.70M
derived: sum of 3 quarters · filed 2023-02-16
-$62.83M
derived: sum of 4 quarters · filed 2023-02-16
2021-03-31-$22.42M
10-Q · filed 2022-04-27
-$65.06M
derived: sum of 2 quarters · filed 2023-02-16
-$65.19M
derived: sum of 3 quarters · filed 2023-02-16
-$94.63M
derived: sum of 4 quarters · filed 2023-02-16
2020-12-31-$42.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16
-$42.78M
derived: sum of 2 quarters · filed 2023-02-16
-$72.21M
derived: sum of 3 quarters · filed 2023-02-16
-$110.86M
10-K · filed 2023-02-16
2020-09-30-$134.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27
-$29.57M
derived: sum of 2 quarters · filed 2021-10-27
-$68.22M
10-Q · filed 2021-10-27
-$73.57M
derived: sum of 4 quarters · filed 2022-02-16
2020-06-30-$29.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28
-$68.08M
10-Q · filed 2021-07-28
-$73.44M
derived: sum of 3 quarters · filed 2022-02-16
-$126.32M
derived: sum of 4 quarters · filed 2022-02-16
2020-03-31-$38.65M
10-Q · filed 2021-04-28
-$44.01M
derived: sum of 2 quarters · filed 2022-02-16
-$96.89M
derived: sum of 3 quarters · filed 2022-02-16
-$138.88M
derived: sum of 4 quarters · filed 2022-02-16
2019-12-31-$5.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16
-$58.23M
derived: sum of 2 quarters · filed 2022-02-16
-$100.22M
derived: sum of 3 quarters · filed 2022-02-16
-$196.62M
10-K · filed 2022-02-16
2019-09-30-$52.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
-$94.87M
derived: sum of 2 quarters · filed 2020-10-29
-$191.27M
10-Q · filed 2020-10-29
-$200.98M
derived: sum of 4 quarters · filed 2021-02-11
2019-06-30-$41.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29
-$138.39M
10-Q · filed 2020-07-29
-$148.10M
derived: sum of 3 quarters · filed 2021-02-11
-$182.54M
derived: sum of 4 quarters · filed 2021-02-11
2019-03-31-$96.40M
10-Q · filed 2020-04-29
-$106.11M
derived: sum of 2 quarters · filed 2021-02-11
-$140.56M
derived: sum of 3 quarters · filed 2021-02-11
-$173.20M
derived: sum of 4 quarters · filed 2021-02-11
2018-12-31-$9.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11
-$44.16M
derived: sum of 2 quarters · filed 2021-02-11
-$76.81M
derived: sum of 3 quarters · filed 2021-02-11
-$139.31M
10-K · filed 2021-02-11
2018-09-30-$34.44M
10-Q · filed 2018-10-23
-$67.09M
derived: sum of 2 quarters · filed 2019-07-25
-$129.60M
10-Q · filed 2019-10-23
-$139.39M
derived: sum of 4 quarters · filed 2020-02-13
2018-06-30-$32.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25
-$95.15M
10-Q · filed 2019-07-25
-$104.94M
derived: sum of 3 quarters · filed 2020-02-13
-$141.22M
derived: sum of 4 quarters · filed 2020-02-13
2018-03-31-$62.51M
10-Q · filed 2019-04-25
-$72.29M
derived: sum of 2 quarters · filed 2020-02-13
-$108.57M
derived: sum of 3 quarters · filed 2020-02-13
-$151.57M
derived: sum of 4 quarters · filed 2020-02-13
2017-12-31-$9.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13
-$46.06M
derived: sum of 2 quarters · filed 2020-02-13
-$89.06M
derived: sum of 3 quarters · filed 2020-02-13
-$157.94M
10-K · filed 2020-02-13
2017-09-30-$36.28M
10-Q · filed 2018-10-23
-$79.28M
derived: sum of 2 quarters · filed 2018-10-23
-$148.16M
10-Q · filed 2018-10-23
-$169.30M
derived: sum of 4 quarters · filed 2019-02-15
2017-06-30-$43.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26
-$111.88M
10-Q · filed 2018-07-26
-$133.02M
derived: sum of 3 quarters · filed 2019-02-15
-$195.71M
derived: sum of 4 quarters · filed 2019-02-15
2017-03-31-$68.88M
10-Q · filed 2018-04-26
-$90.02M
derived: sum of 2 quarters · filed 2019-02-15
-$152.71M
derived: sum of 3 quarters · filed 2019-02-15
2016-12-31-$21.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15
-$83.83M
derived: sum of 2 quarters · filed 2019-02-15
-$208.44M
10-K · filed 2019-02-15
2016-09-30-$62.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26
-$187.30M
10-Q · filed 2017-10-26
2016-06-30-$124.62M
10-Q · filed 2017-07-27
2015-12-31-$227.16M
10-K · filed 2018-02-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76